Drug Trial Radar · NCT02607449
FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis
Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
344
Actual
Start
Dec 2013
Primary completion
Aug 2020
Study completion Oct 2020
Sponsor
- Lead sponsor
- Scientific Center for Anti-infectious Drugs, KazakhstanIndustry
- Sponsor type
- Industry
- Collaborators
- Phthisiopulmonology Center of Almaty, Kazakhstan; National Scientific Center of Phthisiopulmonology, Kazakhstan; Karaganda Medical University; West Kazakhstan Marat Ospanov Medical University; Semey State Medical University; National Center of Phthisiatry, Bishkek, Kyrgyzstan; Invivo laboratory, Kazakhstan
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Drug-resistant tuberculosis is becoming a major problem for the whole humanity, and development of new Anti-TB drugs is of great importance. Since Kazakhstan is a country with the high burden of tuberculosis, the Government of the Republic of Kazakhstan has founded initiative on the development of new Anti-TB drug to treat drug-resistant forms of this infectious disease. JSC "Scientific Center for Anti-infectious Drugs" has developed original drug FS-1 for the treatment of multidrug resistant tuberculosis (MDR-TB).
Conditions
- Tuberculosis, MDR
Interventions
FS-1Drug
FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
PlaceboDrug
Placebo without any active pharmaceutical ingredients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to persistently negative sputum culturesTime frame: 18 months
- Proportion of Patients with persistently negative sputum cultures (SCC)Time frame: 12 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
National scientific center of phthisiopulmonology Ministry of health of the Republic of Kazakhstan
Almaty, Kazakhstan
Center of Phthisiopulmonology of the Public Health Administration of Almaty
Almaty, Kazakhstan
Karaganda Medical University
Karaganda, Kazakhstan
Semey Medical University
Semey, East Kazakhstan, Kazakhstan
West Kazakhstan Marat Ospanov Medical University
Aktobe, West Kazakhstan, Kazakhstan
National Center of Phthisiatry
Bishkek, Kyrgyzstan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.